Hormonal
GLP-1 receptor agonists (GLP-1 RAs) are effective for preoperative weight loss in orthopaedic surgery patients with obesity and type-2 diabetes, reducing surgical risk without increasing postoperative complications.
If you are having orthopaedic surgery and take GLP-1s (like Ozempic or Wegovy), tell your surgeon and anesthesiologist. You likely need to stop taking them a week before (for weekly doses) or on the day of (for daily doses) to prevent stomach issues during anesthesia. This helps ensure your surgery goes smoothly and reduces infection risk.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a promising tool for preoperative weight loss in the patient who is undergoing orthopaedic surgery and has concomitant obesity and type-2 diabetes mellitus.
Why this rating
Based on multiple RCTs and large database studies cited, though some findings are mixed regarding specific complications.
Source
GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes
Rahul Ramanathan et al. · Journal of Bone and Joint Surgery · 2025
DOI 10.2106/jbjs.24.01287
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →